Mezigdomide (CC-92480) is an experimental medication being tested for its effectiveness in treating multiple myeloma, a type of blood cancer. It is being studied to see if it can help stop the cancer from growing or spreading in patients whose cancer has returned or did not respond to previous treatments.

Bortezomib is a medication used to treat multiple myeloma. It works by interfering with the growth of cancer cells, which are eventually destroyed. It is often used in combination with other medications to enhance its effectiveness.

Dexamethasone is a type of steroid medication that helps reduce inflammation and suppress the immune system. In the context of multiple myeloma, it is used to help control the symptoms and improve the effectiveness of other cancer treatments.

Pomalidomide is a medication used to treat multiple myeloma, especially in patients who have not responded to other treatments. It works by helping the immune system attack cancer cells and by stopping the growth of these cells.

Relapsed or Refractory Multiple Myeloma – This is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this condition, the cancer has either returned after treatment (relapsed) or has not responded to treatment (refractory). It typically leads to an overproduction of abnormal plasma cells, which can crowd out healthy blood cells. This can result in symptoms such as bone pain, anemia, kidney problems, and increased risk of infections. The disease progresses as these abnormal cells continue to multiply, potentially causing damage to bones and other organs. Managing the progression of this disease often involves monitoring and adjusting treatment strategies to control the growth of cancerous cells.